2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.19 Weber

PP01.19 Weber - Abstract

Pdf Summary

The study focuses on post-progression outcomes of osimertinib in non-small cell lung cancer patients with EGFR exon 19 deletions or L858R mutations. The research identified 55 patients with resistance mechanisms through testing at the University of Colorado. The resistance mechanisms were categorized as on-target (such as specific EGFR mutations) or off-target (involving other genetic alterations). The study found that the type of resistance mechanism did not significantly impact progression-free survival on subsequent therapy after osimertinib or overall survival from the initiation of osimertinib. Both on-target and off-target groups showed comparable outcomes in terms of survival. Further analysis on a larger dataset is suggested for more conclusive results. The median progression-free survival on the next therapy after osimertinib was 113 days in the on-target group and 180 days in the off-target group, while the median overall survival from the initiation of osimertinib was 950 days in the on-target group and 1,061 days in the off-target group. This study provides insights into the resistance mechanisms of osimertinib in NSCLC patients and their impact on post-progression outcomes, emphasizing the need for more extensive data analysis in the future.

Keywords

osimertinib

non-small cell lung cancer

EGFR exon 19 deletions

L858R mutations

resistance mechanisms

University of Colorado

progression-free survival

on-target mutations

off-target genetic alterations

overall survival